Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade

Diabetic kidney disease is the most frequent cause of end-stage renal disease. This implies failure of current therapeutic approaches based on renin-angiotensin system (RAS) blockade. Recent phase 3 clinical trials of paricalcitol in early diabetic kidney disease and bardoxolone methyl in advanced d...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Gomez, Maria Vanessa, Sanchez-Niño, Maria Dolores, Sanz, Ana Belen, Martín-Cleary, Catalina, Ruiz-Ortega, Marta, Egido, Jesus, Navarro-González, Juan F., Ortiz, Alberto, Fernandez-Fernandez, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485003/
https://www.ncbi.nlm.nih.gov/pubmed/26239562
http://dx.doi.org/10.3390/jcm4061325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485003/
https://www.ncbi.nlm.nih.gov/pubmed/26239562
http://dx.doi.org/10.3390/jcm4061325

Ejemplares similares